Ganglioside GD2 Detection and Targeting in Cancer Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and targeting cancer stem cells (CSCs) are inadequate, as few biomarkers have been identified, and existing therapies often fail to effectively inhibit CSC proliferation, leading to relapse in cancer treatment.
Innovation Solution
The use of ganglioside GD2 and its synthase GD3S as markers for detecting and targeting CSCs, employing antibodies and inhibitors to selectively identify and inhibit GD2-positive cells, which are indicative of cancer stem cells, particularly in GD2-negative cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer therapies are used to treat cancer, then bulk tumor cells are killed, but cancer stem cells survive and cause relapse
Solution Approach 1:
The invention changes the detection parameter from conventional markers (CD44, CD24) to ganglioside GD2 expression status. This parameter change enables identification of CSCs in GD2-negative cancers that would otherwise be undetectable, allowing targeted therapy to eliminate CSCs before they can cause relapse.
Solution Approach 2:
The invention replaces conventional mechanical/chemical detection methods with immunological detection using anti-GD2 antibodies. This substitution provides more specific and sensitive detection of CSCs, enabling precise targeting of the resistant cell population that causes treatment failure.
2Ease of manufacture
If GD2-negative cancer is diagnosed based on bulk tumor cell analysis, then the cancer is classified as non-responsive to GD2-targeted therapy, but CSCs within the tumor may be GD2-positive and targetable
Solution Approach 1:
The invention segments the tumor cell population into bulk tumor cells and CSCs, recognizing that they may have different GD2 expression statuses. By specifically detecting GD2-positive cells within the tumor, the method identifies targetable CSCs even when the overall tumor is GD2-negative, preventing misclassification and missed therapeutic opportunities.
Solution Approach 2:
The invention performs preliminary detection of GD2 expression in tumor cells before therapy selection. This advance detection identifies the presence of GD2-positive CSCs, allowing clinicians to select GD2-targeted therapies that will effectively eliminate CSCs and prevent relapse, rather than using conventional therapies that would fail.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the effective detection and inhibition of CSCs, reducing tumor initiation and growth, and potentially preventing cancer relapse by targeting GD2-positive cells with GD2-binding agents and GD3S inhibitors.
Implementation Method 1
testing the population with an anti-GD2 antibody to detect the presence of GD2 positive cells
Implementation Method 2
detecting elevated expression or activity of ganglioside GD3 synthase (GD3S) in cells, said cells being cancer stem cells
Data Source
AI summary
Methods for determining the presence of cancer stem cells by detecting GD2 expression. Also provided are methods for reducing proliferation of cancer stem cells by contacting the cells with a GD2 targeting agent, such as an anti-GD2 antibody or a GD3 synthase inhibitor. GD3 synthase inhibitor compounds are also provided.